Pharma Focus America

Plexision completes development of PlexAPR™, a rapid blood test to predict transplant rejection

Tuesday, October 11, 2022

Plexision, a biotechnology company, which provides personalized diagnostic testing services for organ transplant patients has completed development of a six-hour blood test to predict organ transplant rejection - PlexAPR™. When combined with other clinical and laboratory information, rapid rejection-risk assessment can allow caregivers to intervene early, while arranging confirmatory biopsies, or during lifelong surveillance of organ health. To learn more, please visit https://plexision.com/transplant-rejection/plexapr.

“Transplant rejection can happen at any time after transplantation and requires lifelong management of anti-rejection medications. Same-day delivery of test results is a valuable addition to personalized rejection-risk assessment and improving outcomes,” said Rajeev Sindhi, CEO of Plexision.

PlexAPR™ is based on the presentation of donor antigen by circulating antigen presenting cells, such as B-cells. The test readout is a personalized index, only applicable to the patient being tested. Patient samples will be tested at the company’s CLIA- and CAP-accredited reference laboratory in Pittsburgh.

Roughly 40,000 patients receive solid organ transplants each year in the US. A limited number of drugs are available to prevent organ rejection. Rapid non-invasive surveillance of organ health provided by Plexision can improve survival and quality of life after transplantation.

Thermo Fisher Scientific - mRNA ServicesFuture Labs Live USA 2024World Vaccine Congress Europe 2024World Orphan Drug Congress 2024Advanced Therapies USA 2024World Orphan Drug Congress Europe 2024